Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recentin in NF1 and plexiform/paraspinal neurofibromas
NCT00326872Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), spinal cord neurofibroma, sponsored by National Cancer Institute. Started May 2006; status: terminated.
02
Drugs
cediranib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)spinal cord neurofibroma
Beyond the preview
Go deeper on NCT00326872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326872.